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Abstract
Background—Breast cancer is the second-leading cause of cancer-related deaths among women 
aged <50 years. Studies on the effects of breast cancer mortality among young women are limited.
Purpose—To assess trends in breast cancer mortality rates among women aged 20–49 years, 
estimate years of potential life lost (YPLL), and the value of productivity losses due to premature 
mortality.
Methods—Age-adjusted rates and rate ratios (RRs) were calculated using 1970–2008 U.S. 
mortality data. Breast cancer mortality rates over time were assessed using Joinpoint regression 
modeling. YPLL was calculated using number of cancer deaths and the remaining life expectancy 
at the age of death. Value of productivity losses was estimated using the number of deaths and the 
present value of future lifetime earnings.
Results—From 1970 to 2008, the age-adjusted breast cancer mortality rate among young women 
was 12.02/100,000. Rates were higher in the Northeast (RR=1.03, 95% CI, 1.02–1.04). The annual 
decline in breast cancer mortality rates among blacks was smaller (−0.68%) compared with whites 
(−2.02%). The total number of deaths associated with breast cancer was 225,866, which accounted 
for an estimated 7.98 million YPLL. The estimated total productivity loss in 2008 was $5.49 
billion and individual lifetime lost earnings were $1.10 million.
Conclusions—Considering the effect of breast cancer on women of working age and the 
disproportionate impact on black women, more age-appropriate interventions with multiple 
strategies are needed to help reduce these substantial health and economic burdens, improve 
survival, and in turn reduce productivity costs associated with premature death.
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Introduction
Breast cancer in women younger than 50 years represents approximately 17% of deaths in 
this age group, making it the second-leading cause of cancer-related deaths among these 
women.1 Although breast cancer in young women (i.e., aged 20–49 years) is rare, it is often 
more aggressive and rapidly growing, and less likely to be amenable to treatment at the time 
of diagnosis.1,2–4
Studies have demonstrated that screening mammography is effective in reducing mortality 
rates associated with breast cancer through early detection, diagnosis, and subsequent 
treatment.5–7 As a result, the U.S. Preventive Services Task Force (USPSTF) recommends 
routine screening for women beginning at age 50 years.8 For women aged 40 to 49 years, the 
USPSTF recommends that the decision to receive regular biennial screening should take into 
account the patient’s values regarding specific screening-associated benefits and harms.8 
The American Cancer Society (ACS) recommends biennial mammography screening 
beginning at age 40 years.9 For average-risk women aged less than 40 years, the ACS 
recommends clinical breast exam (CBE) every 3 years and breast self-exam (BSE) as an 
option starting at age 20 years.9 The USPSTF, however, states insufficient evidence to 
evaluate the additional effects of CBE, but recommends against BSE.8
Given recent public health interest in breast cancer among women younger than 50 years 
(e.g., the Education and Awareness Requires Learning Young [EARLY] Act, Section 10413 
of the Affordable Care Act [Public Law 111–148]),10 it is important to assess how this 
disease affects women in this population. To date, no published studies have reported on 
both the trends and economic effects of breast cancer mortality among young women. Such 
information could shed light on the magnitude of the burden of breast cancer in young 
women and in specific subpopulations. This study examines trends in breast cancer mortality 
rates by racial/ethnic categories and geographic regions, years of potential life lost (YPLL), 
and the value of productivity losses in young women from 1970 through 2008.
Methods
Data
Three broad measures of disease burden were used to quantify the impact of breast cancer 
mortality among young women: mortality rates, YPLL, and the value of productivity loss 
from premature mortality. Breast cancer was identified as the underlying cause of death 
using CDC’s National Vital Statistics Surveillance System11 data on breast cancer mortality 
from 1970 through 2008 and according to the appropriate revisions of the ICD for the study 
years. The following ICD codes were used: ICD-8 code 174 for breast cancer deaths from 
1970 to 1978; ICD-9 codes 174–175 for 1979–1998; and ICD-10 code C50 for 1999–
2008.12–14 Population counts and rates were derived and calculated using SEER*Stat 
software, version 7.0.5 (Surveillance, Epidemiology, and End Results Program). Data were 
extracted for women aged 20–49 years by 10-year age group (i.e., 20–29, 30–39, and 40–
49); racial/ethnic categories; and geographic regions. Many studies have different age cut-
offs when defining a “young woman.”15–18 Based on the considerations of both the USPSTF 
recommended age for breast cancer screening8 and the EARLY Act definition of “young 
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women,”10 a broader, inclusive definition of young women aged between 20 and 49 years 
was chosen.
Statistical Analyses
Breast cancer mortality rates and rate ratios—Breast cancer mortality rates and 
corresponding 95% CIs were computed based on yearly population estimates from the U.S. 
Census Bureau and stratified by race/ethnicity and geographic region. The 95% CIs were 
based on the modified gamma method to ensure proper coverage for small case counts, low 
mortality rates, and populations with age distributions that differed from the standard age 
distribution.19 Estimated rates were expressed per 100,000 population and were age-adjusted 
by the direct method to the SEER 2000 U.S. standard population.20 Rates were based on at 
least 20 deaths in order to obtain stable estimates. To compare mortality rates across 
geographic regions, rate ratios (RRs) and 95% CIs were calculated using the South as the 
reference region.
Annual percent change—Joinpoint regression software (version 3.4.3) was used to 
examine the annual percentage change in breast cancer mortality rates. This modeling 
software uses a Monte Carlo permutation test to identify points where the direction or 
magnitude of the trend changes and fits a model containing the fewest number of trend 
segments.21 A detailed description of the Joinpoint modeling approach is presented in the 
Appendix A (available at www.ajpmonline.org). Trends in mortality rates were calculated by 
racial/ethnic categories, age groups, and geographic regions. The significance of calculated 
trends were assessed using a two-sided t-test with p<0.05.
Estimating years of potential life lost—The U.S. life tables from 1970 through 2008 
were used to obtain average life expectancy for women across racial/ethnic categories. Using 
the calculated average life expectancy and the age of death, the potential years of life 
remaining were calculated. From these data, YPLL, YPLL per death, and age-adjusted 
YPLL rates per 100,000 U.S. population were calculated for each racial/ethnic group. 
Detailed methods used are presented in Appendix A (available at www.ajpmonline.org).
Estimating the value of mortality-related productivity losses—Previously 
published methods were used to estimate the value of lifetime mortality-related productivity 
losses in 2008.22–24 To account for future inflation, a zero (0%), 3%, and 5% annual 
discount rate was applied to estimate the present value of foregone future lifetime earnings 
(PVFLE). In addition to estimating the PVFLE lost due to breast cancer mortality at the 
national level, cost of premature death was also estimated at the individual level. To appraise 
uncertainty in the estimated PVFLE, the lower and upper bounds of the 95% CI of the death 
rates were used. All estimated PVFLE were converted to 2008 U.S. dollars using the 
consumer price index, available at www.bls.gov/cpi/data.htm. Detailed description of the 
estimation methods are presented in Appendix A (available at www.ajpmonline.org).
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Results
Breast Cancer Mortality Rates and Rate Ratios Among Young Women
The overall results for women aged 20–49 years were presented; however, the results for 
specific 10-year age groups were reported in Appendix B (available at 
www.ajpmonline.org). From 1970 through 2008, the age-adjusted breast cancer mortality 
rate among women aged 20–49 years was 12.02/100,000 (95% CI=11.97–12.07) for all 
racial/ethnic groups; 11.45/100,000 (95% CI=11.40–11.50) for whites; and 17.97/100,000 
(95% CI=17.79–18.14) for blacks. For all racial/ethnic groups, rates were slightly higher in 
the Northeast compared to the South (RR=1.03, 95% CI=1.02–1.04), whereas rates were 
slightly lower in the Midwest and lowest in the West (Table 1). The estimated rates among 
whites followed the same geographic pattern observed among all racial/ethnic groups. 
Compared with all racial/ethnic groups and whites, blacks had substantially higher age-
adjusted breast cancer mortality rates in all U.S. regions. Significantly lower mortality rates 
among blacks occurred in the Northeast (RR=0.91, 95% CI=0.89–0.94) compared to the 
South. Detailed results are presented in Appendix B (available at www.ajpmonline.org).
Annual Percent Change (APC)
Among all races/ethnicities, overall breast cancer mortality rates significantly decreased 
from 1970 to 1981 (APC=–1.33%), followed by a nonsignificant increase (0.22% annually) 
between 1981 and 1989, and a sharp decline during 1989–2008 (−3.11% annually; Table 2). 
All regions experienced a significant decrease in breast cancer mortality rates across all 
years; however, the South had a nonsignificant increase in breast cancer mortality rates from 
1980 to 1990 (0.83%). Trends in breast cancer mortality rates among blacks were unstable 
from 1970 to 2008 compared with all racial/ethnic groups and whites (Table 2). Most 
notably, blacks experienced periods of significant increases during periods when overall 
mortality rates were decreasing. Significant increases among blacks were found nationwide 
between 1976 and 1988 (1.92% annually); in the South between 1976 and 1989 (2.27%); in 
the Midwest between 1970 and 1987 (0.89%) and between 1987 and 2008 (1.63%); and in 
the West between 1970 and 1988 (1.61%). Detailed estimates on trends in breast cancer 
mortality rates are presented in Appendix C (available at www.ajpmonline.org).
Overall, the decline in breast cancer mortality rates among blacks aged 20–49 years since 
1970 has been very small (−0.68%) compared with whites (−2.02%) and all racial/ethnic 
groups (−1.77%; Figure 1). From 1970 through 2008, decreasing trends were significant for 
all age groups and for all racial/ethnic categories. In addition, mortality rate reductions were 
greatest among whites across all age groups, with the largest reduction among women aged 
20–29 years. However, by examining mortality trends over 10-year time periods, substantial 
differences were found across both racial/ethnic categories and time periods (Figure 2). 
From 1970 through 2008, the largest significant annual percent decreases occurred among 
whites during 1990–1999 (4.10%), among all racial/ethnic groups during 1990–1999 
(−3.56%), and among blacks during 2000–2008 (−2.18%). The only significant increase in 
mortality rates was found among blacks in the 1980s, with an increase of 1.80% per year 
(Figure 2).
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Years of Potential Life Lost
From 1970 through 2008, the total number of deaths associated with breast cancer in women 
aged 20–49 years was 225,866 for all racial/ethnic groups, 179,557 for whites, and 41,357 
for blacks. These deaths accounted for an estimated 7.98 million YPLL (95% CI=7.97–7.99 
million) in all racial/ethnic groups; 6.32 million YPLL (95% CI=6.31–6.33 million) in 
whites; and 1.48 million YPLL (95% CI, 1.480–1.484 million) in blacks (Table 3). 
Regardless of racial/ethnic category, on average, a woman who died from breast cancer 
between the ages of 20 and 49 years from 1970 through 2008 was estimated to lose more 
than 35 years of potential life.
The extent to which the observed increases (or decreases) in the number of breast cancer 
deaths during different time periods over- or under-estimates premature mortality was also 
examined. Using the 1970s as a reference period, it was estimated that in the 2000s, a 6.12% 
decrease in breast cancer mortality for all racial/ethnic groups would account for a 4.59% 
increase in YPLL (Table 3). This implies that premature deaths observed in the 2000s were 
experienced more in women at a younger age than that observed in the 1970s. During the 
same time period, a 65.80% increase in breast cancer deaths among blacks would increase 
YPLL by 82.86%. Detailed estimates by racial/ethnic group and by specific age group are 
presented in Appendix D (available at www.ajpmonline.org).
Mortality-related Productivity Losses
In 2008, the estimated total lifetime productivity loss associated with breast cancer mortality 
in young women aged 20–49 years discounted at a 3% rate was $5.49 billion per year (Table 
4). Among the total productivity losses, lost market productivity accounted for $3.06 billion 
(55.74%). When the values of both total and market productivity losses were discounted at 
an annual rate ranging from 5% to 0%, the estimates ranged from $4.23 to $8.81 billion for 
lifetime total productivity losses and $2.47 to $4.39 billion for lifetime market productivity 
losses. At an individual level, cost per death was estimated to be $1.10 million (discount rate 
range from 5% to 0%: $0.85–$1.77 million) for the total productivity loss and $0.62 million 
(discount rate range from 5% to 0%: $0.50–$0.89 million) for the market productivity loss. 
Detailed estimates by racial/ethnic groups and by specific age group on the PVFLE due to 
breast cancer mortality are presented in Appendix E (available at www.ajpmonline.org). The 
estimated sensitivity analysis of the PVFLE among all racial/ethnic groups and among 
whites and blacks separately were close to the estimates presented in Table 4. These results 
were presented in Appendix F (available at www.ajpmonline.org).
Discussion
The findings in this study provide estimates of the substantial health and economic burden 
associated with breast cancer mortality to young women, their families, and society. These 
findings underscore the importance of developing aggressive educational initiatives for 
young women with breast cancer. Furthermore, this study indicates that considerable 
progress has been made in reducing breast cancer mortality rates, but more progress is 
needed to reduce rates and improve outcomes, particularly among young black women. To 
our knowledge, there are no studies that have used a combination of measures to quantify 
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trends in mortality rates, YPLL, and the value of productivity loss from premature breast 
cancer mortality among women aged 20–49 years. This study also provides a baseline of 
health and economic indicators, which can be used to assess future progress in reducing the 
disease, mortality, and health effects of breast cancer among young women.
To put these findings into context, during the past 39 years, breast cancer mortality rates 
have significantly declined (APC=−1.77%) among women aged <50 years. At the same 
time, the incidence rates have increased, but at a smaller rate (0.30%). Conversely, breast 
cancer mortality rates among women aged >50 years have declined at a much smaller rate 
(−0.70%) compared with the rate of women aged <50 years. Breast cancer incidence rates 
for women aged >50 years significantly increased (0.80%) compared with a lower rate 
observed for women aged <50 years. In the past 40 years, incidence of breast cancer was 
much higher in the older age group and mortality rate was higher in the younger age group.
This study follows patterns similar to a study by Max et al.,26 although the study was 
specific to California women with differences in age distribution and study population. 
Similarly, Bradley et al.27 used the human capital approach to ascertain the value of lost 
productivity attributable to premature death, although the findings from this study are not 
comparable because of differences in age groups and time spans. Further, in the past decade, 
many studies have reported temporal trends in breast cancer mortality rates in the general 
population but not in subpopulations such as women aged 20–49 years.28–30 As a result, the 
findings on trends in mortality rates may not be directly comparable to previously reported 
rates.
From 1970 through 2008, breast cancer mortality rate in younger women aged 20–29 years 
in all racial/ethnic groups was estimated to decline significantly more than those in other age 
groups. These findings indicate that although younger women may have poorer breast cancer 
survival outcomes than older women,31 over time, more are surviving from this disease. This 
may be due, at least in part, to the increased use of tamoxifen, adjuvant chemotherapy, and 
other chemopreventive agents, which has led to declines in breast cancer mortality rates 
across several age groups, including younger women.32,33 A study by a Danish group con-
firmed this observation and found that breast cancer prognosis was worse for young women 
who were not treated with chemotherapy.34
Although breast cancer is relatively uncommon in young women, clinical studies have 
shown that they have a more aggressive form of the disease, larger tumors, a higher 
prevalence of adverse prognostic outcomes, fewer hormone receptor–positive tumors, earlier 
and more frequent local recurrences, and poorer overall survival compared with older 
women.14–16,35–39 Further, studies have reported that not only is breast cancer a 
heterogeneous disease with different morphologies, breast cancer is expressed in diverse 
molecular profiles with important clinical differences among populations in terms of 
incidence, mortality, diagnosis, treatment, and prognosis.40,41 These clinical differences are 
more profound in black women, who bear the greatest impact among all racial/ethnic groups 
according to this study.
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Many studies have reported that black women are more likely to have estrogen receptor–
negative tumors that unfavorably influence their use of tamoxifen, a preventive drug of 
choice for premenopausal women; in addition, a higher proportion of black women have 
more aggressive tumors, which are clinically associated with poor health outcomes.42–45 
Over time and even in recent years (i.e., 2000–2008), the observed decline in breast cancer 
mortality rates has been significantly smaller in black women compared with other racial/
ethnic groups. This suggests the need for more age-appropriate interventions to improve 
patient outcomes that target young black women and their healthcare providers. Initiatives to 
increase the awareness of breast cancer and quality of care in black communities may help 
black women to identify breast lumps, be knowledgeable about changes to their breasts, and 
participate in decisions regarding options for treatment. Such initiatives could help reduce 
the widening mortality disparity between young black women and young white women 
observed in this study.
Limitations
This study has some limitations. First, mortality data were based on death certificates, and 
the quality of the information recorded can vary. However, a previous study concluded that 
there were no problems with coding of breast cancer as cause of death,46 and another study 
has verified the quality of demographic data on death certificates.47 Second, the human 
capital approach27 was used to calculate the PVFLE lost due to breast cancer mortality in 
young women. This approach assumes that an individual produces a stream of earnings that 
is valued only through employment. Because the approach is based on market wages and, on 
average, American women earn less than their male counterparts at every level of 
educational attainment,48 it may have underestimated productivity losses from breast cancer 
mortality among young women. Further, the human capital approach also fails to recognize 
the costs of intangibles, including pain and suffering, the psychosocial consequences of 
cancer, and reductions in the quality of life.49 Third, the analysis excludes morbidity costs 
associated with breast cancer, which include productivity loss from individuals with breast 
cancer before they die, costs of medical treatment, nonmedical costs such as those associated 
with time spent seeking cancer treatment and care,50 and productivity losses for caregivers. 
Finally, multiple factors that might explain the differences in black mortality rates compared 
with all racial/ethnic groups and whites were not considered. These factors may include 
prognostic, socioeconomic, demographic, and behavioral access to health care and health 
insurance.
Conclusion
In his 1991 address to the Society for Epidemiologic Research, Sir Richard Doll suggested 
that monitoring cancer trends in young adults would be beneficial because it could serve as 
an early warning system or, in the case of a declining trend, an early indication of the 
effectiveness of a preventive strategy or risk-reducing agent.51 These findings provide direct 
evidence that in the past four decades, breast cancer mortality in young women have not 
decreased as fast in black women as in white women. Further, this study also reported 
substantial health and economic burden associated with breast cancer mortality in young 
women.
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Given the findings from this study and considering that this cancer affects women who are in 
their productive years with maximum family and social responsibilities, this implies that the 
nation and families are losing current and future productivity and it underscores the need for 
more-aggressive interventions. Decision makers may have a role in creating and sustaining 
multifaceted prevention programs, including intensive treatment regimens, educational 
initiatives, and initiating systems and environmental change to reduce the burden, improve 
survival, and in turn, reduce productivity costs associated with premature death.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Annual percent change in breast cancer mortality rates in young women by age group and 
racial/ethnic category, US., 1970–2008.
*The annual percent change is significantly different from 0 (two-sided p<0.05).
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Figure 2. 
Annual percent change in breast cancer mortality rates in young women age 20–49 years by 
racial/ethnic category and time period, US., 1970–2008.
*The annual percent change is significantly different from 0 (two-sided p<0.05).
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Table 1
Age-adjusted breast cancer mortality rates, rate ratios in young women by racial/ethnic categories, U.S., 1970–
2008a
Racial/ethnic category Rateb (95% CI) RR (95% CI)
All race/ethnicity 12.02 (11.97–12.07) —
 South 12.32 (12.23–12.40) 1.00 (ref)
 Northeast 12.69* (12.58–12.80) 1.03* (1.02–1.04)
 Midwest 12.09* (11.99–12.19) 0.98* (0.97–0.99)
 West 10.79* (10.69–10.90) 0.88* (0.87–0.89)
White 11.45 (11.40–11.50) —
 South 11.12 (11.03–11.22) 1.00 (ref)
 Northeast 12.43* (12.31–12.55) 1.12* (1.10–1.13)
 Midwest 11.56* (11.45–11.66) 1.04* (1.03–1.05)
 West 10.83* (10.72–10.94) 0.98* (0.96–0.99)
Black 17.97 (17.79–18.14) —
 South 18.34 (18.09–18.58) 1.00 (ref)
 Northeast 16.73* (16.35–17.10) 0.91* (0.89–0.94)
 Midwest 18.45 (18.04–18.86) 1.01 (0.98–1.03)
 West 17.61* (17.03–18.20) 0.96* (0.93–0.99)
a
Rates are for young women aged 20–49 years. Detailed age group–specific and time period–specific rates are presented in Appendix B (available 
at www.ajpmonline.org).
b
Rates are per 100,000 population and are age adjusted to the 2000 U.S. standard population (See Day 1996.25 Current population reports no. 25–
1130. Washington, DC: U.S. Bureau of the Census, 1996). 95% CIs (Tiwari mod).
*
The rate ratio (RR) indicates the rate is significantly different from the rate for the South (p<0.05).
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Table 4
Present value of discounted future lifetime productivity losses due to breast cancer mortality among young 
women aged 20–49 years by race/ethnicity, U.S., 2008a
Race/ethnicity
Discounted total cost ($ x 1 million)b Discounted total cost per death ($ x 1 million)b
Lifetime total productionc
3% (5%–0%)
Lifetime market productiond
3% (5%–0%)
Lifetime total 
productionc
3% (5%–0%)
Lifetime market 
productiond
3% (5%–0%)
All race/ethnicity $5488.6 ($4230.1–8805.1) $3057.6 ($2465.9–4394.9) $1.10 ($0.85–1.77) $0.62 ($0.50–0.89)
White $3920.4 ($3099.1–6207.7) $2198.6 ($1775.4–3153.1) $1.09 ($0.86–1.73) $0.61 ($0.50–0.88)
Black $1323.2 ($2148.9–2071.5) $743.8 ($597.5–1075.5) $1.11 ($0.86–1.80) $0.62 ($0.50–0.90)
aAll costs were expressed in 2008 U.S. dollars.
b
Discounted cost per death was calculated by dividing the estimated amount of productivity losses by the number of deaths that occurred 
prematurely.
c
Lifetime total production consists of earnings received through the labor market and household services.
d
Lifetime market production consists of earnings received only through the labor market.
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